← Oncology Approval Tracker

FDA DECISION ·

Brukinsa tablets

zanubrutinib · BeOne Medicines USA

Accelerated approvalNew formulationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 160 mg tablet formulation with obinutuzumab for adults with relapsed or refractory follicular lymphoma after at least two systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

This formulation action retains accelerated status for the obinutuzumab combination in relapsed follicular lymphoma.

What research teams should watch

Keep oral dispensing aligned with obinutuzumab visits and record the two qualifying prior systemic treatment lines.

PRIMARY RECORDS

Sources